Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24 2019 we hereby confirm that there is no deviation or variation in the use of funds raised through Preferential Issue of Convertible Warrants from the objects stated in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated 15th June 2021.
Accordingly a Nil Statement of Deviation duly reviewed by the Audit Committee of the Company for the Quarter ended September 30 2021 is given in "Annexure A".
Marksans Pharma: Statement On Deviation Or Variation Of Funds Raised Through Preferential Issue Of Convertible Warrants.
November 10, 2021
Download PDF
Marksans Pharma
Informed fund ideas, better judgment. Every month. Mutual Fund Insight, every month since October 2002.
Take charge. Know more. Keep more. Mutual Fund Insight helps you do all three — every month